BioTech

We explore which cell therapy, genetic editing and other innovative technologies are democratizing access to and costs of healthcare, and enabling better quality of life. 

Elvie Raises $42 Million, Shows Femtech Is Thriving

On Our Radar: Deals we are paying attention to for their impact on industry. Get with it, bro culture. Femtech is thriving and able to generate cash big time. The women’s health company Elvie announced on April 2, that it has raised its third financing round, a $42...

Startups Using Agility, Experience, to Move the Needle on Opioid Crisis

From a social network for addicts to robots that test sewage water for traces of drugs, startups and private companies are applying innovative solutions to one of the nation’s most pressing problems -- its opioid epidemic. Over 11.4 million people have misused...

Musk’s Neuralink Promises Innovation But Requires Trust and Proof

While Elon Musk’s brain implant company, Neuralink, has announced plans to begin human patient tests before the end of next year, experts believe proving the technology’s competence may take longer. In an event yesterday, held primarily for recruiting more...

TA Associates Acquires Stake in Indian Fertility Hospital Chain

On Our Radar: Deals we are paying attention to for their impact on industry. Private equity firm TA Associates acquired a minority stake in Indira IVF, a leading fertility hospital chain in India. The Boston-based TA Associates said its investment will go into growing the infertility treatment provider...

Biotech Novoheart to Collaborate With AstraZeneca on Heart-in-a-Jar Model

Karma_News Summary_Heart in a Jar
Stem cell biotech company Novoheart and pharmaceutical giant AstraZeneca announced they would be partnering to develop the first test tube model of human heart failure, also called heart-in-a-jar. The companies said they would use heart tissue engineered by Novoheart...

Glycomine Lands $33 Million for Trials of Therapy for Rare Genetic Disorder

Genetic Research, A human sample being pipetted into a multi well plate for genetic analysis sitting on DNA sequence
With a goal to stamp out a rare disease that takes the lives of about one-fifth of the children it affects, biotechnology company Glycomine is finding deep-pocketed support from investors including Danish pharmaceutical giant Novo Nordisk.  The San Carlos,...

Microbiome Experts Call Out Technology’s Limits, Saying it’s Still Early Days of Personalized Medicine

Karma_News Analysis_probiotics
While the number of microbiome-focused products and investments rises, the science remains in a nascent stage, and expectations for the industry may be ahead of reality, according to speakers at a Bard College symposium on Thursday. Martha Carlin, CEO...

Biotech Startup Is Vying to Improve Memory Through Brain Implants

If Nia Therapeutics succeeds, brain chips will enter medical clinics in three years that will  provide memory generation for all patients suffering from brain injuries or disorders. Michael Kahana, a University of Pennsylvania researcher, and Dan Rizzuto, a neuroscientist,...

Ancestry’s IPO Talk Shows How Consumer DNA Testing Has Matured

Surging popularity of home DNA kits that enable consumers to uncover secrets of their ancestry and health risks has fueled speculation that the industry is set for further disruption this year. Ancestry.com, the world’s largest direct-to-consumer genetic-testing company, is getting ready for an initial public...

Thermo Fisher Scientific Gets Serious About Gene Therapy with Brammer Bio Bid

On Our Radar: Deals we are paying attention to for their impact on industry. Thermo Fisher Scientific, the world’s biggest manufacturer of scientific instruments, bid for Brammer Bio LLC on March 24 in a $1.7 billion cash deal. The move would give the diagnostic and testing equipment giant...

Juliana Garaizar: “There’s going to be a real return on investment [in fertility]…”

Strategic Investors: Profiles of investors with strategies to consider. Juliana Garaizar manages the $25 million Texas Medical Center (TMC) Venture Fund, which provides early stage funding for promising innovators in healthcare and life sciences. She also leads the Consumer Fund for the innovative Portfolia FemTech Fund, a female-led...

The Specter of Theranos Is Haunting Biotech Startups

The final chapter in Elizabeth Holmes’ story as an entrepreneur is set to begin next year with her fraud trial scheduled for summer of 2020. But medical device startups and investors may find the fallout from the crash and burn of her...

GHO Capital, Spying European Healthcare Opportunities, Raises Record Fund

Karma_News Summary_GHO Capital
Private equity firm GHO Capital Partners, reflecting European investors’ bullishness for healthcare, topped expectations by raising almost $1.1 billion for its second fund.  The total, surpassing GHO’s $885 million goal, is a record for a fund targeting European healthcare,...

Creating Health’s Future: 5,000+ Leading Health Executives to Converge at HLTH 2019

HLTH
This content is brought to you in partnership with HLTH. How do we create the future of health? That’s the question HLTH is seeking to answer.  From Oct. 27-30, more than 5,000 executives, investors and entrepreneurs...

Frazier Healthcare Tops Target for Life Sciences Fund, Grabbing $617M on Soaring Biotech Demand

Frazier Healthcare raised a greater-than-expected $617 million for its latest fund, as private investors’ appetite for healthcare innovation shows no sign of slowing. Frazier Life Sciences X, the company’s third life sciences fund, is slated to invest in biotech products...

Blackstone Teams With Swiss Firm Ferring For $570 Million Effort to Make Cancer Killing Gene Therapy

Karma_News Summary_Blackstone invests in Ferring
Blackstone, which last year started up a life sciences investing arm, is pouring $400 million into a venture with a Swiss pharmaceutical firm to develop and commercialize a gene therapy for bladder cancer. Blackstone’s investment seeks to spur FerGene,...

Brave New World: Investors Bet $100 Million on Success of Pig-to-Human Organ Transplants

Karma_News Summary_eGenesis
The transplantation of pig organs into humans moved a step closer to reality after investors upped their bets, pouring in $100 million, on the work of biotechnology company eGenesis. The Cambridge, Massachusetts company uses new gene-editing technologies to make...

Researchers Use Gene Modification to Defeat Rice-Killing Disease

Karma_News Summary_CRISPR
Researchers successfully edited the genome of strains of rice grown in Southeast Asia and West Africa to block a pathogen that ravages yields of the staple crop, the latest example of gene modification that may reduce hunger throughout the world.Bacterial blight is...

U.S. Wants More Domestic Pharma Production as Quality Concerns Persist; Lawmakers Worry About China’s Power

Karma_News Summary_Pharmaceuticals
As concerns rise about the growing percentage of U.S. drugs manufactured in China, U.S legislators are seeking measures to bring more of the industry back onshore. During a congressional hearing Wednesday, regulators and lawmakers in both parties expressed interest...

Magic Mushrooms Move Closer to Mainstream Medicine As VC-Backed Compass Touts Safety, “Positive Mood Alteration”

Karma_News Summary_Magic mushrooms
Magic mushrooms as a treatment for depression took another step toward mainstream acceptance as a venture capital-backed company announced positive results from a psilocybin trial. Compass Pathways’ psilocybin medication was “well-tolerated in healthy volunteers,” a first step in seeking...

Private Equity, Biotech Industry Worried Pelosi Drug Plan Would Be ‘Destructive,’ Slow Innovation

Karma_News Summary_Pelosi drug plan
Private equity and venture capital firms, which have poured billions of dollars in biotech firms, are opposing House Speaker Nancy Pelosi’s plan to cut drug prices, saying it would stifle the small firms that are often the source of new medications.

FDA Will Consider Biogen’s Controversial Drug as First New Alzheimer’s Treatment Drug in 17 Years

Karma_News Summary_Alzheimer's treatment
A controversial drug that treats the early stages of Alzheimer’s disease might become the first medication for the disease in 17 years to win regulatory approval. Biogen Inc. said it plans to submit a regulatory filing for its aducanumab...

Despite Concerns About Gene Editing, Venture Investors, Big Pharma Remain a Captive Audience

Karma_News Summary_Gene Editing Big Pharma
A year after a Chinese scientist unleashed a storm of condemnation by announcing the birth of a baby whose genes he had edited, the medical and scientific community has yet to agree on rules guiding research into the practice.

Japan Set to Create Hybrid Mammal for Organ Donation, Unleash Ethical Storm

In a move certain to set medical ethicists’ heads spinning, stem-cell researchers in Japan are launching a study with an aim to create hybrid animals out of rats and mice that will produce human organs for medical transplant, according to media reports.

FDA Warns Medical Devices May Be Vulnerable to Hackers, Highlighting Vulnerability of Equipment to Attacks

Karma_News Analysis_Medical device cybersecurity
Pacemakers, insulin pumps and other medical devices using software called IPnet contain potential flaws that make them vulnerable to cyber attacks, the Food and Drug Administration has warned.The agency is working with medical device makers to determine which devices, whether in health-care...

SpringWorks Therapeutics Scores $125M in Series B Financing Through Perceptive Advisors

On Our Radar: Deals we are paying attention to for their impact on industry. Clinical-stage biopharmaceutical company SpringWorks Therapeutics, Inc. moved closer on April 1 to advancing medicines for patients with severe rare diseases and cancer when it closed a $125 million Series B preferred stock financing...

Johns Hopkins to Expand Psychedelics-As-Medicine Research With $17 Million Center

large magic mushroom
Magic mushrooms as treatment for depression, PTSD other issues is getting a major boost at Johns Hopkins University, as researchers continue efforts, sometimes backed by venture capital, to find therapies in alternative, overlooked places. Johns Hopkins, which has been...

Mouse Microbiome Study May Point to Better Human Antibiotic Tolerance

Karma_News Analysis_Microbiome
A new study into how antibiotics affect beneficial bacteria living in human guts suggests ways in which dietary changes may reduce the medicines’ side effects and generate new treatments.Brown University researchers, conducting a study in mice, found that changes in the animals’...

Poseida CEO Eric Ostertag on Standing Out in Crowded Biotech Field

Sound Businesses: Profiles of companies and business models we are keeping an eye on. It’s been an interesting year for Poseida Therapeutics, the human therapeutics company that spun out of Transposagen Biopharmaceuticals in 2015. Poseida in January filed for an IPO, only to have it...

Death Toll From Heart Disease is Spiking, as Private Investors Race to Fund Treatments

Once thought manageable, heart disease is making a dangerous comeback in the U.S., killing more than ever with a surprising toll on city dwellers. While doctors cite increasing stress and spreading sedentary lifestyles, private investors are funding medical startups...
- Advertisement -